Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aslan Pharma Approved to List Shares on Taiwan's Main Board

publication date: Jan 24, 2017
Aslan Pharma of Singapore was approved to list on Taiwan's Taipei Stock Exchange, Taiwan's main board. Before being admitted to TPEX, a company must first be listed for six months on Taiwan's OTC market, sometimes known as the GreTai exchange. Aslan has met that requirement, and it will, presumably, at some point conduct a public fundraising event, though the company has not yet disclosed its plans. Founded in 2010, Aslan raised $23 million in pre-IPO venture capital last July, bringing its total VC funding to more than $100 million. More details....

Stock Symbol: (TPEX: 6497)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital